Charnwood Molecular is an award-winning, UK-based CRO which has been providing expert drug discovery and development support for over 20 years. Clients range from virtual start-ups to established global agrochemical, materials chemistry, diagnostic, biotechnology and pharmaceutical companies. All clients benefit from a proactive and open approach, geared towards rapidly advancing projects towards important key decision points and beyond.
An expert scientific team, which enjoys the benefit of substantial and varied industrial and academic experience, focusses on providing intellectual input and enabling the rapid advancement of projects. Charnwood Molecular is a results-driven, dynamic company committed to delivering success for global clients. Their scientists seek to achieve research excellence in their work and are passionate about maintaining their market-leading status.
The expertise and service offerings span areas from customised bioassay development, computational, synthetic and medicinal chemistry to process research and development. As a team with wide-ranging experience gained within fine chemical, pharmaceutical and biotech companies, they can provide expertise at all stages of your research project, aiming for intellectual input and novelty in your programs.
Charnwood Molecular‘s portfolio of services is wide and currently includes: Customised bioassay development Medicinal Chemistry (design, synthesis and multi-parameter optimisation of drug molecules for discovery projects; computational chemistry and emerging synthetic technologies) Custom Synthesis preparation of key chemical intermediates on up to 20-litre scale Chemical Development and Process Research Services including route design, development and optimization.
Analytical Chemistry Support. For more information please visit the website: www.charnwood-molecular.com or contact the Business Development team: info@charnwood-molecular.com Our experience and technical knowledge can rapidly identify molecule challenges with protocols which emphasize efficient use of resources. Applying our understanding of drug physicochemical properties, we can offer tailored and rational preclinical formulation development.
Using the Developability Classification System (DCS) as our framework, we examine how the physicochemical characteristic of a compound may affect oral absorption and bioavailability, determining risk and suggesting formulation strategies. Using a rapid excipient screening approach, we can provide preclinical formulations which enhance drug solubility and overcome in vivo sources of pharmacokinetic variability. In vitro testing using biorelevant models can demonstrate formulation abilities to promote supersaturation and resist unfavorable situations such as pH-mediated precipitation and food effects.
